CSF false-bottom tube

Low bind CSF collection tube for Alzheimer's disease biomarkers

SARSTEDT

- ✓ Excellent recovery thanks to low-binding properties
- ✓ Routine-use primary container for sample collection and automated analytics
- ✓ Patient-friendly sample volume of 2.5 ml
- ✓ Cost-effective alternative to PET scan
- ✓ Reliable pre-analytics for optimum sample integrity

CSF false-bottom tube - helps improve reliability in the early detection of Alzheimer's disease

Aducanumab has been approved by the 'U.S. Food and Drug Administration (FDA)' as an Alzheimer agent to slow the progression of Alzheimer's disease. Approval for the European market is also expected. The hope that this news brings will increase the need for early diagnosis.

Particularly in the early stages of dementia illnesses, the determination of Alzheimer's disease biomarkers (ß-amyloid, total tau & phospho-tau) increasingly supports CSF-based nuclear medicine dementia diagnostics.

The new CSF false-bottom tube, in conjunction with Roche's new generation of Elecsys® CSF immunoassays, creates the perfect conditions for reliable pre-analytics to support the current development in research, diagnostics and treatment of Alzheimer's disease.

CSF false-bottom tubes

Order no	Material	Volume	Length & Ø	Design	Packaging
63.614.625	Polypropylene	2.5 ml	75 x 13 mm	Low-Binding	Individually wrapped, sterile 100/outer box

Optimized analytics through low-binding properties

For adult patients with cognitive impairments who are being evaluated for Alzheimer's disease (AD) and other potential causes, the determination of AD biomarkers in cerebrospinal fluid (CSF) is an extremely cost-effective and routine-use alternative to nuclear medical amyloid positron emission tomography (PET) scans.

Alzheimer's disease biomarkers have the ability to bind to surfaces, in turn complicating pre-analytical conditions. This especially applies to ß-amyloid fragments.[1-5] The binding takes place very quickly, even after just five minutes, a concentration loss (analyte loss) of 20% could be detected.[3]

In light of this, a new CSF sample tube was developed using a special material. The SARSTEDT CSF false-bottom tube combines for the first time, optimal low-binding properties with the demands of a routine-use sample tube for a very special sample. This ensures greater compatibility of the analytical results.

Pre-analytics & analytics

The purpose of a standardized pre-analytical protocol for AD diagnostics is that it helps minimize systematic influences from pre-analytics, for example, and enables consistent cutoff values.

The CSF false-bottom tube has the best recovery of Alzheimer's disease biomarkers with Roche's new generation of immunoassays. Based on this, it is defined by Roche as "the CSF primary container" and is recommended as optimal for new standardized pre-analytical protocols[1] in conjunction with the new generation of Elecsys® CSF immunoassays.



SARSTEDT

SARSTEDT

SARSTEDT, Inc.
1025 St. James Church Road
P.O. Box 468
Newton, NC 28658 - 0468

Toll free: +1 800 257 5101
Fax: +1 828 465 4003

customerservice.us@sarstedt.com
www.sarstedt.com

References:

[1] Hansson O, Rutz S, Zetterberg H, et al. Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF; Alzherimer Dement. 2020;12:e12137. https://doi.org/10.1002/dad2.12137

[2] Toombs J, Paterson RW, Lunn MP, Nicholas JM, Fox NC, Chapman MD, et al. Identification of an important potential confound in CSF AD studies: aliquot volume. Clin Chem Lab Med 2013; 51:2311-7.

[3] Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, et al. Risk of Alzhereimer´s disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimers Dis 2012;31:13-20.

[4] Bjerke M, Portelius E, Minthon L, Wallin A, Ancharsater H, Ancharsater R, et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010;2010:1-11.

[5] Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem 2006;52:332-4.

25_887_0000_501

SARSTEDT